Current Ratio: A liquidity ratio that measures a company's ability to pay short-term obligations. Calculated as: Total Current Assets / Total Current Liabilities
Iovance Biotherapeutics, Inc. (IOVA) had Current Ratio of 3.20 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$263.50M |
|
$-390.98M |
|
$173.18M |
|
$90.32M |
|
$666.86M |
|
$-403.36M |
|
$10.31M |
|
$-393.05M |
|
$-393.05M |
|
$-390.98M |
|
$-390.98M |
|
$-390.98M |
|
$-390.98M |
|
$-403.36M |
|
$-363.23M |
|
357.35M |
|
357.35M |
|
$-1.09 |
|
$-1.09 |
|
| Balance Sheet Financials | |
$442.69M |
|
$131.11M |
|
$470.48M |
|
$913.17M |
|
$138.36M |
|
-- |
|
$76.23M |
|
$214.59M |
|
$698.58M |
|
$419.26M |
|
$698.58M |
|
411.94M |
|
| Cash Flow Statement Financials | |
$-302.41M |
|
$47.50M |
|
$300.77M |
|
$122.05M |
|
$169.06M |
|
$47.01M |
|
$61.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
|
Current Ratio |
3.20 |
-- |
|
-- |
|
-- |
|
0.00 |
|
34.28% |
|
-153.08% |
|
-153.08% |
|
-137.85% |
|
-149.16% |
|
-148.38% |
|
$-336.24M |
|
-- |
|
-- |
|
-- |
|
0.29 |
|
3.35 |
|
3.20 |
|
114.21 |
|
-55.97% |
|
-93.25% |
|
-42.82% |
|
-55.97% |
|
$1.70 |
|
$-0.94 |
|
$-0.85 |
|